Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Leerink Partnrs

Oruka Therapeutics (NASDAQ:ORKA) was upgraded by stock analysts at Leerink Partnrs to a “strong-buy” rating in a note issued to investors on Tuesday, Zacks.com reports.

A number of other equities research analysts have also issued reports on ORKA. Leerink Partners began coverage on Oruka Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $44.00 target price on the stock. Wedbush began coverage on shares of Oruka Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $40.00 price objective on the stock. Lifesci Capital assumed coverage on shares of Oruka Therapeutics in a research report on Monday. They issued an “outperform” rating and a $41.00 target price for the company. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock. Finally, TD Cowen assumed coverage on Oruka Therapeutics in a report on Monday. They issued a “buy” rating for the company. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $41.25.

Oruka Therapeutics Trading Down 4.1 %

ORKA opened at $25.38 on Tuesday. Oruka Therapeutics has a 1 year low of $18.72 and a 1 year high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.